Real-time Estimate
Cboe BZX
16:53:25 02/05/2024 BST
|
5-day change
|
1st Jan Change
|
18.35
USD
|
+0.49%
|
|
+6.73%
|
-32.29%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
7,338
|
12,884
|
10,168
|
2,786
|
3,283
|
2,226
|
-
|
-
|
Enterprise Value (EV)
1 |
7,338
|
11,896
|
10,370
|
2,912
|
3,255
|
2,518
|
2,677
|
2,899
|
P/E ratio
|
-93
x
|
-49.6
x
|
-25
x
|
-4.24
x
|
-6.32
x
|
-5.44
x
|
-6.05
x
|
-6.79
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
34.2
x
|
44.9
x
|
27.2
x
|
6.2
x
|
5.82
x
|
3.35
x
|
2.77
x
|
2.22
x
|
EV / Revenue
|
34.2
x
|
41.5
x
|
27.8
x
|
6.48
x
|
5.77
x
|
3.79
x
|
3.34
x
|
2.9
x
|
EV / EBITDA
|
-103
x
|
-140
x
|
-26.7
x
|
-5.84
x
|
-7.46
x
|
-7.49
x
|
-9.45
x
|
-10.6
x
|
EV / FCF
|
-111
x
|
-84.9
x
|
-36.5
x
|
-7.53
x
|
-9.42
x
|
-7.91
x
|
-9.78
x
|
-13.7
x
|
FCF Yield
|
-0.9%
|
-1.18%
|
-2.74%
|
-13.3%
|
-10.6%
|
-12.6%
|
-10.2%
|
-7.31%
|
Price to Book
|
9.23
x
|
9.95
x
|
15.8
x
|
46.4
x
|
20.7
x
|
-18
x
|
-7.3
x
|
-4.63
x
|
Nbr of stocks (in thousands)
|
93,906
|
99,972
|
101,656
|
102,436
|
121,380
|
121,885
|
-
|
-
|
Reference price
2 |
78.14
|
128.9
|
100.0
|
27.20
|
27.05
|
18.26
|
18.26
|
18.26
|
Announcement Date
|
24/02/20
|
24/02/21
|
23/02/22
|
23/02/23
|
22/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
214.4
|
286.7
|
373.7
|
449.5
|
563.9
|
663.7
|
802.6
|
1,001
|
EBITDA
1 |
-70.96
|
-85.18
|
-388.7
|
-498.9
|
-436.3
|
-336.2
|
-283.3
|
-273.5
|
EBIT
1 |
-82.37
|
-255
|
-411
|
-544.4
|
-564.7
|
-403.8
|
-362.7
|
-296.1
|
Operating Margin
|
-38.42%
|
-88.92%
|
-110%
|
-121.1%
|
-100.14%
|
-60.84%
|
-45.19%
|
-29.58%
|
Earnings before Tax (EBT)
1 |
-69.72
|
-245.9
|
-384.5
|
-653.4
|
-478.8
|
-398.9
|
-365
|
-299.7
|
Net income
1 |
-75.65
|
-253.8
|
-405.7
|
-654.6
|
-479.4
|
-398.5
|
-363.7
|
-332.6
|
Net margin
|
-35.29%
|
-88.51%
|
-108.57%
|
-145.61%
|
-85.02%
|
-60.04%
|
-45.31%
|
-33.23%
|
EPS
2 |
-0.8400
|
-2.600
|
-4.000
|
-6.410
|
-4.280
|
-3.355
|
-3.016
|
-2.688
|
Free Cash Flow
1 |
-65.85
|
-140.1
|
-284.1
|
-386.9
|
-345.5
|
-318.2
|
-273.8
|
-211.9
|
FCF margin
|
-30.72%
|
-48.86%
|
-76.02%
|
-86.07%
|
-61.26%
|
-47.93%
|
-34.11%
|
-21.17%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
24/02/20
|
24/02/21
|
23/02/22
|
23/02/23
|
22/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
94.78
|
108.1
|
96.1
|
109.1
|
117.4
|
126.9
|
128.7
|
137.2
|
143
|
155.1
|
150.1
|
160.8
|
168
|
183.7
|
182
|
EBITDA
1 |
-101.7
|
-92.12
|
-111.6
|
-120
|
-122.6
|
-133.3
|
-123.4
|
-108.1
|
-101.8
|
-102.9
|
-89.68
|
-103.2
|
-85.53
|
-81.72
|
-86
|
EBIT
1 |
-107.3
|
-98.21
|
-123.3
|
-130.3
|
-144.6
|
-146.1
|
-134.1
|
-119.6
|
-113.5
|
-197.5
|
-108.4
|
-104.7
|
-100.3
|
-95.62
|
-101.7
|
Operating Margin
|
-113.2%
|
-90.84%
|
-128.34%
|
-119.4%
|
-123.16%
|
-115.15%
|
-104.15%
|
-87.22%
|
-79.38%
|
-127.38%
|
-72.25%
|
-65.1%
|
-59.66%
|
-52.06%
|
-55.87%
|
Earnings before Tax (EBT)
1 |
-107.4
|
-72.3
|
-123.3
|
-229
|
-161.9
|
-139.3
|
-133.3
|
-72.28
|
-85.61
|
-187.6
|
-106.8
|
-105.5
|
-102.9
|
-99.01
|
-107.1
|
Net income
1 |
-107.5
|
-90.91
|
-123.2
|
-229.4
|
-162
|
-139.9
|
-133.5
|
-72.77
|
-86.1
|
-187
|
-107.3
|
-102.9
|
-100.4
|
-96.76
|
-101.5
|
Net margin
|
-113.45%
|
-84.09%
|
-128.23%
|
-210.21%
|
-137.98%
|
-110.28%
|
-103.74%
|
-53.06%
|
-60.2%
|
-120.63%
|
-71.52%
|
-64.02%
|
-59.74%
|
-52.68%
|
-55.74%
|
EPS
2 |
-1.060
|
-0.8900
|
-1.210
|
-2.250
|
-1.580
|
-1.360
|
-1.300
|
-0.6700
|
-0.7300
|
-1.580
|
-0.8994
|
-0.8614
|
-0.8385
|
-0.8055
|
-0.8451
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
04/11/21
|
23/02/22
|
05/05/22
|
04/08/22
|
03/11/22
|
23/02/23
|
09/05/23
|
03/08/23
|
06/11/23
|
22/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
202
|
126
|
-
|
292
|
451
|
673
|
Net Cash position
1 |
-
|
989
|
-
|
-
|
28.7
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-0.5198
x
|
-0.2529
x
|
-
|
-0.8689
x
|
-1.593
x
|
-2.461
x
|
Free Cash Flow
1 |
-65.9
|
-140
|
-284
|
-387
|
-345
|
-318
|
-274
|
-212
|
ROE (net income / shareholders' equity)
|
-11.8%
|
-24.2%
|
-41.7%
|
-186%
|
-438%
|
-385%
|
-52.3%
|
-41.3%
|
ROA (Net income/ Total Assets)
|
-9.76%
|
-15.7%
|
-18.1%
|
-34.3%
|
-28.2%
|
-17.4%
|
-17.6%
|
-13.8%
|
Assets
1 |
775
|
1,617
|
2,238
|
1,907
|
1,698
|
2,292
|
2,065
|
2,405
|
Book Value Per Share
2 |
8.470
|
13.00
|
6.340
|
0.5900
|
1.300
|
-1.010
|
-2.500
|
-3.940
|
Cash Flow per Share
2 |
-0.5200
|
-1.070
|
-2.060
|
-3.030
|
-2.900
|
-2.300
|
-1.210
|
0.4400
|
Capex
1 |
18.7
|
36.2
|
75
|
77.5
|
20.5
|
48.7
|
56.1
|
67
|
Capex / Sales
|
8.73%
|
12.62%
|
20.08%
|
17.23%
|
3.63%
|
7.34%
|
6.99%
|
6.69%
|
Announcement Date
|
24/02/20
|
24/02/21
|
23/02/22
|
23/02/23
|
22/02/24
|
-
|
-
|
-
|
Last Close Price
18.26
USD Average target price
39.41
USD Spread / Average Target +115.84% Consensus |
1st Jan change
|
Capi.
|
---|
| -32.29% | 2.23B | | -19.07% | 11.03B | | +54.37% | 3.5B | | -14.31% | 2.16B | | -27.19% | 1.54B | | +32.44% | 1.12B | | -3.28% | 737M | | -23.25% | 477M | | -41.72% | 411M | | +17.30% | 342M |
Bio Diagnostics & Testing
|